Glucocorticoids are the mainstay of CAH treatment with the double aim of preventing adrenal insufficiency and suppressing androgen excess through a direct negative feedback to the pituitary adrenocorticotropic hormone (ACTH) secretion [1, 3]. This evidence concerns the gene POMC and hyperandrogenism.